CAMALLERGY
Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of patients suffering worldwide from food allergies. Camallergy’s lead product, CA002, is a second-generation novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment regimen are based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK.
CAMALLERGY
Industry:
Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.camallergy.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.92 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Global Site Tag Amazon Pound Sterling Typekit
Current Advisors List
Current Employees Featured
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - Camallergy
Jonathan Milne
Jonathan Milne investment in Angel Round - Camallergy
Official Site Inspections
http://www.camallergy.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Camallergy"
About - Camallergy
Camallergy is developing a pipeline of products to treat food allergies, starting with peanut allergy. Peanut allergy: the highest priority. Peanut allergy is highly prevalent. It affects 1.4 to 3% of children and at least 0.5% of adults in high …See details»
Camallergy - Crunchbase Company Profile & Funding
Camallergy’s lead product is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment regimen …See details»
Camallergy Inc - Crunchbase Company Profile & Funding
Camallergy Inc . Connect to CRM . Save . Summary. People. Technology. Signals & News. About. ... Recent News & Activity. There is no recent news or activity for this profile. Details. …See details»
Camallergy Company Profile 2024: Valuation, Funding & Investors
Camallergy General Information Description. Developer of an oral immunotherapy drug intended to focus on food allergies. The company's drug is a patient-centric treatment of peanut …See details»
Cambridge Allergy - Overview, News & Similar companies
Camallergy is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of people worldwide who suffer from food allergies. …See details»
Camallergy - Contacts, Employees, Board Members, Advisors
Organization. Camallergy . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. ... Camallergy has 3 …See details»
Team — Camallergy
Mike represents Dr Jonathan Milner, PhD, who was Camallergy’s lead investor through its early stages. Jonathan is the founder of Abcam plc, and an experienced entrepreneur and investor. He is passionate about supporting UK …See details»
Camallergy - VentureRadar
Camallergy’s lead product, CA002, is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The …See details»
Camallergy - LinkedIn
Camallergy | 585 followers on LinkedIn. Developing life-changing treatments for food allergy | Millions of people suffer from food allergy. We develop pioneering treatments so they can live …See details»
Camallergy | Cambridge - Facebook
Camallergy, Cambridge, Cambridgeshire. 53 likes. Millions of people suffer from food allergy We develop pioneering treatments so they can live free from...See details»
Camallergy Provides Corporate Update and Prepares to Advance …
Nov 6, 2019 Camallergy’s lead product, CA002, is a novel oral immunotherapy for the treatment of peanut allergies designed to offer “bite-proof” protection to patients within 14 weeks of therapy.See details»
Camallergy and OnDosis Announce a Groundbreaking Partnership …
Nov 29, 2023 Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company spun out from Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK. The company …See details»
Company to Begin Phase 3 Trials of New Peanut Allergy OIT …
Mar 9, 2021 From Camallergy.com. Here is a video from the company’s website describing their program: Click to visit sponsor A phase 1 study of CA002 in 22 children aged 4 to 17 years in …See details»
Camallergy - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Camallergy and OnDosis forge groundbreaking partnership to ...
Nov 24, 2023 The safety and efficacy of the Camallergy’s treatments are subject to confirmation in phase 3 clinical trials. They are investigational and not yet approved by regulatory agencies. …See details»
Clinical trials - Camallergy
Early phase clinical trials. The phase 3 programme builds on the unprecedented results generated in our early phase clinical trials. STOP2 showed strong, clinically relevant results in children, …See details»
Technology — Camallergy
The safety and efficacy of the Camallergy’s treatments are subject to confirmation in phase 3 clinical trials. They are investigational and not yet approved by regulatory authorities. SubscribeSee details»
News & media - Camallergy
23.03.21 Camallergy awarded £1.1m funding under Innovate UK Biomedical Catalyst Award for novel peanut allergy treatment . 08.01.21 Camallergy’s UK-based manufacturing facility …See details»
Science — Camallergy
Camallergy’s approach: at-home up-dosing. Tiny, daily dose increments replace large, fortnightly dose increases. Removing large dose increases aims to reduce side effects. We aim to enable …See details»